Learning From the Immune System of Long-term Pancreatic Cancer Survivors

November is pancreatic cancer awareness month.

A look at the statistics from the SEER database is a stark reminder that pancreatic cancer is a deadly disease with a five-year survival rate of a mere 8.2 percent. Unfortunately, the last 30 years has not seen any significant improvement in survival for patients with this disease. Pancreatic cancer is projected to become the second leading cause of deaths due to cancer in the United States by 2030.

Read More

What Advances are Researchers Making in Treating Glioblastoma, McCain’s Cancer?

As we learned recently, Senator John McCain was diagnosed with glioblastoma multiforme, an aggressive form of central nervous system tumor that starts in the brain or spinal cord. It accounts for about 45 percent of all primary brain tumors, with about 11,000 diagnoses in men, women, and children each year.

Read More

Biomarkers and Liquid Biopsy for Early Detection of Colorectal Cancer

AACR is the proud Scientific Partner for Stand Up To Cancer (SU2C), and for Colorectal Cancer Awareness Month, we asked the co-leader of the SU2C–Dutch Cancer Society Dream Team on Molecular Early Detection of Colorectal Cancer, Victor Velculescu, MD, PhD, about the work of the Dream Team and other efforts in this field of cancer research.

Read More

Stepping Into the Era of Combination Cancer Therapies, Part 2: Combining Targeted Therapies

In my first post in this series highlighting some of the studies presented at the AACR Annual Meeting 2015 that hold promise for combination cancer therapies, I discussed clinical trials …

Read More

Behind the Scenes: Recognizing and Supporting Progress in Cancer Research at the AACR Annual Meeting

In addition to providing a forum for attendees to learn, network, and share information and ideas, the Annual Meeting presents a valuable opportunity for the AACR to recognize our research grant recipients, who range from promising early-career investigators to established researchers, and to honor researchers who have made significant contributions to the cancer research enterprise.

Read More